Cogstate 1Q27 Business Update
Released
Released
Announcement PDF
| Page 1
ASX Announcement
12 October 2026
Cogstate 1Q27 Business Update
All figures in US$, unless stated
Cogstate Ltd (ASX:CGS), a global leader in clinical trial endpoint data quality and digital cognitive assessments,
today releases a business update for the quarter ended 30 September 2026 (“1Q27”).
Net sales contracts executed during 1Q27 totalled $25.1 million. The result reflects continued execution of the
Company’s strategy to combine scientific leadership in CNS endpoint quality with a growing channel partnership
ecosystem, allowing sponsors to access Cogstate’s expertise while working with their preferred clinical technology
providers.
A table of recent quarterly results for net sales contracts executed is provided below for context:
FY27
US$ Million
FY26
US$ Million
FY25
US$ Million
Sep Quarter 25.13 21.42 11.40
Dec Quarter N/A 20.29 8.90
Mar Quarter N/A 25.44 7.01
Jun Quarter N/A 21.85 13.95
Total Sales Contracts Executed 25.13 89.00 41.26
The September quarter sales results demonstrated Cogstate’s ability to win market share in mood disorders,
including the competitive win of five Phase 3 trials in either bipolar or depression, across two customers,
contributing over 80% of the total contract sales value executed during the quarter.
Sponsors commonly retain providers from earlier phases of development when progressing to Phase 3 studies.
The Company's channel partnership strategy was an important factor in its appointment to these programs. By
enabling sponsors to work with their preferred data capture and clinical technology providers, while leveraging
Cogstate's expertise in endpoint quality and complex global study execution, Cogstate was able to secure work
that may historically have been more difficult to win independently.
Contracted Revenue
The table below provides analysis of Cogstate’s contracted revenue position at 30 September 2026:
Contracted Revenue
(incl. revenue recognised in 1Q27)
US$ Million
PCP
(incl. revenue recognised in 1Q26)
US$ Million
Growth
%
1H27 $31.7 $23.0 38%
FY27 (incl. 1H27) $56.8 $39.2 45%
FY28-FY33 $86.9 $62.6 39%
Overall Total $143.7 $101.8 41%
*PCP = Previous Corresponding Period
| Page 2
Contracted FY27 revenue increased to $56.8 million at 30 September 2026, from $48.3 million at 30 June 2026.
The $25.1 million in new contracts executed during 1Q27 contributed $8.4 million to contracted FY27 revenue,
representing an in-year revenue yield of 34%.
This yield was lower than typically expected for first-quarter sales, reflecting a lower-than-usual licence fee
contribution of 7% (compared to a historical average range of 20%-25%) and the significant proportion of longer-
duration Phase 3 trials. The resulting revenue profile strengthened coverage for FY28, with contracted revenue
increasing to $39.7 million at 30 September 2026, from $31.4 million at 30 June 2026.
Annual General Meeting
Investors are reminded that the 2026 Annual General Meeting (AGM) of Cogstate Limited will be held as a hybrid
meeting at 10:00am AEDT on Thursday, 15 October 2026, being at Level 13, 664 Collins Street, Docklands,
Victoria, and as a virtual meeting.
Virtual Attendance At The AGM
Shareholders who have an existing account with Cogstate share registry, Automic, will be able to watch, listen and
vote online. Shareholders who do not have an account with Automic are strongly encouraged to register for an
account as soon as possible and well in advance of the Meeting to avoid any delays on the day of the Meeting.
An account can be created via the following link https://portal.automic.com.au/investor/home and then clicking on
“register” and following the prompts. Shareholders will require their holder number (Securityholder Reference
Number (SRN) or Holder Identification Number (HIN)) to create an account with Automic.
The meeting will be recorded and made available to all shareholders via the Cogstate investor website.
This announcement was authorised for release by Cogstate Ltd CEO, Brad O’Connor. For further information
contact: investor@cogstate.com
0
10
20
30
40
50
60
FY'27 FY'28 FY'29 FY'30 FY'31+
US$
Million
Expected Contracted Revenue Recognition
Clinical Trials Healthcare
| Page 3
About Cogstate
Cogstate Ltd (ASX: CGS) is a global Central Nervous System (CNS) endpoint innovations company that partners
with drug developers to power complex neuroscience studies. Cogstate uniquely specializes in the science and
service of CNS measurement to ensure clinical trial endpoint data is as accurate as it is actionable. Our applied
technology solutions include fit-for-purpose data quality programs, advanced analytics, and digital cognitive testing
to identify clear signals for confident decision-making. Building upon 25 years of customized collaborations,
Cogstate is accelerating the next generation of CNS therapies. In the Healthcare market, Cogstate seeks to provide
primary care physicians and consumers with brief, accurate and scientifically validated digital measures of
cognition, with a focus on easy to use, self-administered tests that inform patients and save physician time. For
more information, please visit www.cogstate.com.
Explanatory Notes
1. Sales contracts: In the Clinical Trials division, Cogstate enters into contracts (“sales contracts”) with both
pharmaceutical and biotechnology companies for the provision of Cogstate technology and services, for use in
clinical research trials, to determine the extent to which their investigational compound is impacting the
cognition of the patient population. The contract value will differ for each clinical trial, depending upon the
scope of the technology and services provided by Cogstate, as well as the complexity and length of the trial. An
increase in the total value of sales contracts executed will increase the revenue backlog and will, over time,
result in an increase to revenue recognised by Cogstate.
2. Calculation of revenue from the Clinical Trials division: Revenue from sales contracts is recognised over
the life of the contract. The length of a clinical trial can vary from several months for a phase 1 study and up to
4-5 years for a phase 3 study. Revenue is recognised based upon the achievement of pre-determined
milestones. During each period, revenue may be recognised from (i) contracts in the backlog at the beginning
of the period, as well as (ii) sales contracts executed during the period. Usually there is a time lag between an
increase or decrease in the level of sales contracts executed and a corresponding change to recognised
revenue.
Important Notices
Past performance
Past performance is given for illustrative purposes only and should not be relied upon as (and is not) an indication
of Cogstate's views on its future financial performance or condition. Past performance of Cogstate cannot be relied
upon as an indicator of (and provides no guidance as to) the future performance of Cogstate. Nothing contained in
this announcement, nor any information made available to you is, or shall be relied upon as, a promise,
representation, warranty, or guarantee, whether as to the past, present, or future.
Future performance and forward-looking statements
This announcement contains certain “forward-looking statements.” The words “expect,” “anticipate,” “estimate”,
“intend”, “believe”, “guidance”, “should”, “could”, “may”, “will”, “predict”, “plan” and other similar expressions are
intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial
position and performance are also forward-looking statements. Forward-looking statements, opinions and
estimates provided in this announcement are based on assumptions and contingencies that are subject to change
without notice and involve known and unknown risks and uncertainties and other factors that are beyond the
control of Cogstate, its directors and management. Forward-looking statements are provided as a general guide
only and should not be relied upon as an indication or guarantee of future performance.
Actual results, performance or achievements may differ materially from those expressed or implied in such
statements and any projections and assumptions on which these statements are based. These statements may
assume the success of Cogstate's business strategies, including the fact that the results of any of those strategies
| Page 4
will be realised in the period for which the forward-looking statement may have been prepared or otherwise. For
example, Cogstate's performance in any one financial period is sensitive to whether or not contracts are signed in
that period, or a subsequent period, and the rate of enrolment in trials of its customers, which are influenced by
factors that are outside of Cogstate's control.
Readers are cautioned not to place undue reliance on forward-looking statements and except as required by law or
regulations, none of Cogstate, its representatives or advisers, assumes any obligation to update these forward-
looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of
achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters
contained in this announcement. The forward-looking statements are based on information available to Cogstate as
at the date of this announcement. Except as required by law or regulation (including the ASX Listing Rules), none
of Cogstate, its representatives or advisers undertakes any obligation to provide any additional or updated
information, whether as a result of a change in expectations or assumptions, new information, future events or
results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance
are also forward-looking statements.
Share your feedback
Discover